Advertisement
MDT vs SNN
Which Stock Would AI Choose? Medtronic (MDT) vs. Smith & Nephew (SNN) Stock Comparison
Key Takeaways
- Both MDT and SNN operate in the medical devices sector, with MDT holding a larger scale and broader portfolio across cardiovascular, diabetes, and neuroscience segments.
- Recent market activity shows MDT delivering stronger revenue growth momentum, including 8.7% reported growth in its latest quarter, while SNN reported more modest underlying revenue gains of 2.3% in the first half.
- Analyst sentiment has turned positive for MDT with multiple price target increases ahead of upcoming earnings, contrasting with SNN lowering its full-year revenue outlook to approximately 4%.
- MDT benefits from new product cycles in high-growth areas like pulsed field ablation and robotics, whereas SNN shows strength in sports medicine but faces challenges in U.S. orthopaedics.
- Both companies maintain dividend programs and share repurchase activity, with SNN executing a $500 million buyback program and MDT increasing its quarterly dividend.
- Relative performance in recent weeks favors MDT with a one-month gain of about 6.5%, compared to more muted movements for SNN.
Introduction
Medtronic (MDT) and Smith & Nephew (SNN) represent two established players in the global medical technology industry. This comparison examines their business models, recent financial results, stock performance, and market positioning to assist investors and traders evaluating opportunities within the healthcare equipment sector. The analysis draws on verifiable data from earnings reports and analyst commentary covering developments in recent weeks and months. Professionals monitoring sector rotation, earnings momentum, or relative valuation may find the side-by-side review useful for portfolio allocation decisions.
MDT Overview and Recent Performance
Medtronic plc develops and manufactures medical devices spanning cardiovascular, medical-surgical, neuroscience, and diabetes care. In recent market activity, the stock has traded near $91, reflecting a one-month gain of approximately 6.5% amid broader sector interest. The company reported fiscal third-quarter revenue of $9.0 billion, up 8.7% on a reported basis and 6.0% organically, exceeding guidance and marking its strongest top-line growth in ten quarters. Key drivers included double-digit expansion in Cardiac Ablation Solutions and continued progress with new platforms such as the Hugo surgical robot. Analysts have responded with raised price targets ahead of first-quarter fiscal 2027 results scheduled for early September, citing an emerging product cycle and share gains in core markets.
SNN Overview and Recent Performance
Smith & Nephew plc focuses on orthopaedics, sports medicine, ENT, and advanced wound management. The stock has recently traded near $29 following first-half 2026 results that showed revenue of $3.1 billion, up 2.3% on an underlying basis. Trading profit rose 8.1% to $566 million and adjusted earnings per share increased 11%, supported by efficiency savings and resilient performance in sports medicine. Management lowered full-year underlying revenue growth guidance to around 4% due to softness in U.S. orthopaedics, while reaffirming targets for trading profit, free cash flow, and return on invested capital. The company continues a $500 million share repurchase program and raised its interim dividend by 4%.
Trending AI Robots
Tickeron operates a platform featuring hundreds of AI trading bots that analyze and trade thousands of different tickers across global markets. Only those demonstrating the strongest alignment with prevailing market conditions, consistent performance metrics, and suitable risk profiles are featured in the curated Trending AI Robots section. Available bots cover a wide range of trading styles, strategies, timeframes, and ticker sets, with performance statistics that vary by individual algorithm. This diversity allows users to explore options matching specific objectives without relying on a single approach. For additional details on current selections, visit the Trending AI Robots page.
Head-to-Head Comparison
Medtronic operates at significantly larger scale with diversified exposure across high-growth cardiovascular and diabetes segments, while Smith & Nephew maintains a more focused portfolio centered on orthopaedics and sports medicine. Recent momentum favors MDT through stronger organic revenue expansion and multiple new product launches, whereas SNN has emphasized margin expansion and capital returns amid softer top-line trends. Both companies face typical sector risks including regulatory approvals, reimbursement pressures, and supply-chain costs, yet MDT appears positioned for broader international share gains while SNN targets recovery in U.S. orthopaedics. Market sentiment, as reflected in recent analyst actions, shows more upward revisions for MDT compared with tempered expectations for SNN.
Tickeron AI Verdict
Based on observable factors such as recent revenue growth consistency, new product catalysts, and relative analyst positioning, Tickeron’s AI models currently assign a higher probability of favorable near-term momentum to MDT over SNN. The assessment reflects stronger trend alignment in key segments and an active earnings catalyst window, while acknowledging that execution on guidance and broader market conditions could influence outcomes for either name.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDT is a StrongBuy and SNN is a StrongBuy.
| MDT | SNN | MDT / SNN | |
| Capitalization | 116B | 11.6B | 1,000% |
| EBITDA | 10.3B | 1.57B | 655% |
| Gain YTD | -3.675 | -14.913 | 25% |
| P/E Ratio | 22.40 | 18.71 | 120% |
| Revenue | 37.5B | 6.3B | 595% |
| Total Cash | 8.82B | 754M | 1,170% |
| Total Debt | 28.2B | 3.79B | 745% |
MDT | SNN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 79 | 54 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 4 Undervalued | 3 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 68 | 92 | |
PRICE GROWTH RATING 1..100 | 36 | 73 | |
P/E GROWTH RATING 1..100 | 59 | 89 | |
SEASONALITY SCORE 1..100 | n/a | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SNN's Valuation (3) in the Medical Specialties industry is in the same range as MDT (4). This means that SNN’s stock grew similarly to MDT’s over the last 12 months.
SNN's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as MDT (100). This means that SNN’s stock grew similarly to MDT’s over the last 12 months.
MDT's SMR Rating (68) in the Medical Specialties industry is in the same range as SNN (92). This means that MDT’s stock grew similarly to SNN’s over the last 12 months.
MDT's Price Growth Rating (36) in the Medical Specialties industry is somewhat better than the same rating for SNN (73). This means that MDT’s stock grew somewhat faster than SNN’s over the last 12 months.
MDT's P/E Growth Rating (59) in the Medical Specialties industry is in the same range as SNN (89). This means that MDT’s stock grew similarly to SNN’s over the last 12 months.
| MDT | SNN | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 52% | 1 day ago 61% |
| Stochastic ODDS (%) | 1 day ago 54% | 1 day ago 60% |
| Momentum ODDS (%) | 1 day ago 54% | 5 days ago 57% |
| MACD ODDS (%) | 1 day ago 68% | N/A |
| TrendWeek ODDS (%) | 1 day ago 55% | 1 day ago 55% |
| TrendMonth ODDS (%) | 1 day ago 50% | 1 day ago 59% |
| Advances ODDS (%) | 9 days ago 53% | 9 days ago 58% |
| Declines ODDS (%) | 1 day ago 56% | 1 day ago 56% |
| BollingerBands ODDS (%) | 1 day ago 54% | 1 day ago 68% |
| Aroon ODDS (%) | 1 day ago 36% | 1 day ago 61% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MDT’s FA Score shows that 1 FA rating(s) are green while SNN’s FA Score has 1 green FA rating(s).
- MDT’s FA Score: 1 green, 4 red.
- SNN’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MDT’s TA Score shows that 4 TA indicator(s) are bullish while SNN’s TA Score has 4 bullish TA indicator(s).
- MDT’s TA Score: 4 bullish, 4 bearish.
- SNN’s TA Score: 4 bullish, 4 bearish.
Price Growth
MDT (@Medical/Nursing Services) experienced а -3.41% price change this week, while SNN (@Medical/Nursing Services) price change was -4.75% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -5.01%. For the same industry, the average monthly price growth was -8.95%, and the average quarterly price growth was -6.66%.
Reported Earning Dates
MDT is expected to report earnings on Nov 24, 2026.
SNN is expected to report earnings on Nov 06, 2026.
Industries' Descriptions
@Medical/Nursing Services (-5.01% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
SNN and
Correlation & Price change
A.I.dvisor indicates that over the last year, SNN has been loosely correlated with MDT. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if SNN jumps, then MDT could also see price increases.
| Ticker / NAME | Correlation To SNN | 1D Price Change % | ||
|---|---|---|---|---|
| SNN | 100% | -0.43% | ||
| MDT - SNN | 50% Loosely correlated | -0.72% | ||
| SYK - SNN | 48% Loosely correlated | +2.06% | ||
| OFIX - SNN | 47% Loosely correlated | +2.76% | ||
| ENOV - SNN | 46% Loosely correlated | +4.73% | ||
| GEHC - SNN | 44% Loosely correlated | -0.48% | ||
More | ||||